LNTH · Lantheus Holdings, Inc.
AI read · Neutral
The AI's read
The sale removes an owned manufacturing operation, but PharmaLogic will still make lutetium Lu 177 dotatate for Lantheus under the supply deal. The companies did not share the sale terms, so the source does not show how much cash Lantheus receives or how its costs may change. The deal also awaits regulatory review and other closing steps. Together, these facts leave the company’s outlook little changed.